PT  - JOURNAL ARTICLE
AU  - A Karim
AU  - C Kook
AU  - D J Zitzewitz
AU  - J Zagarella
AU  - M Doherty
AU  - J Campion
TI  - Species differences in the metabolism and disposition of spironolactone.
DP  - 1976 Nov 01
TA  - Drug Metabolism and Disposition
PG  - 547--555
VI  - 4
IP  - 6
4099  - http://dmd.aspetjournals.org/content/4/6/547.short
4100  - http://dmd.aspetjournals.org/content/4/6/547.full
SO  - Drug Metab Dispos1976 Nov 01; 4
AB  - The absorption, excretion and metabolism of [22-14C]spironolactone was compared in Charles River rats, beagle dogs and rhesus monkeys. The drug was administered at the fixed dose of 5 mg/kg po and iv. From the po/iv ratios of the areas under the plasma radioactivity-time curves, the gastrointestinal absorption of the drug was estimated to be 82% in the rat, 62% in the dog, and 103% in the monkey. The absolute bioavailability of a pharmacologically active metabolite, canrenone, was 57% in the dog and 48% in the monkey. Spironolactone was extensively metabolized in all three species and differences existed in the composition of the metabolites in their plasma, urine, and feces. The amount of radioactivity that was excreted in the urine and feces of all three species was similar after either po or iv administration of the drug. The cumulative average excretion of radioactivity in the urine as percentage of the po dose in 6 days was 4.69% in the rat (N = 5), 18.5% in the dog (N = 3), and 46.0% in the monkey (N = 3). In the feces, the corresponding excretion values were 74.2, 69.3 and 40.1%, respectively. Canrenone excretion in the urine constituted 0.65% of the po dose in the rat, 0.82% in the dog, and 5.86% in the monkey, whereas the excretion of total fluorogenic metabolites constituted 1.1, 1.9, and 12.1% respectively. Comparison of animal data with those published for humans indicated that the disposition and metabolism of spironolactone in the rhesus monkey, rather than those in the rat or the dog, was closest to that in man.